| ABSTRACT Objective:To observe the clinical effects, adverse reactions and impacts on inflammatory cytokines of carbocisteine on patients with stable COPD. Methods: 114 patients were randomly divided into observation group and control group, the control group was treated with conventional therapy, the observation group received carbocisteine additionally. All treated for 12 months. Pulmonary function, 6 minute walking distance (6MWT), the frequency of acute exacerbation were compared, the St george's respiratory questionnaire(SGRQ) was used to evaluate the quality of life, the level of inflammatory cytokines (IL-1β, IL-6, IL-8 and TNF-α) in induced sputum were determined, the adverse reactions were recorded. Results:After treatment, compared with those before treatment, the pulmonary function, 6MWT and the frequency of acute exacerbation improved greatly in both groups (P<0.05); for the observation group, the 6MWT and frequency of acute exacerbation were better than those of control group (P<0.05). The SGRQ scores decreased greatly in both groups (P<0.05), and some scores were better in the observation group (P<0.05). The level of inflammatory cytokines in induced sputum decreased greatly in both groups (P<0.05), and those in observation group were lower (P<0.05). The occurrence rate of adverse reactions was similar (P>0.05).Conclusion:For the patients with stable COPD, carbocisteine could increase their sports ability and quality of life, decrease the frequency of acute exacerbation, reducing airway inflammation might be its mechanisms. |
